Eradication (Group HpE)* | Placebo (Group Hp+)† | p Value | |
---|---|---|---|
All values are median (range). | |||
*Within HpE group comparison between baseline and end of treatment: antral gastritis: p<0.0001, suggesting significant resolution of gastritis after H pylori eradication; corpus gastritis: p<0.0001, suggesting significant resolution of gastritis after H pylori eradication; antral atrophy: p = 0.07; corpus atrophy: p = 0.32; antral intestinal metaplasia: p = 0.11; corpus intestinal metaplasia: p = 1.0. | |||
†Within Hp+ group comparison between baseline and end of treatment: antral gastritis: p = 0.15; corpus gastritis: p<0.0001, suggesting significant increase in severity of gastritis; antral atrophy: p = 0.28; corpus atrophy: 0.32; antral intestinal metaplasia: p = 0.053; corpus intestinal metaplasia: p = 0.32. | |||
Antral gastritis | |||
Baseline | 4 (1–6) | 4 (1–6) | 0.28 |
End of treatment | 1 (0–4) | 3 (1–6) | <0.0001 |
Corpus gastritis | |||
Baseline | 3 (0–6) | 3 (0–6) | 0.56 |
End of treatment | 1 (0–4) | 4 (0–6) | <0.0001 |
Antral atrophy | |||
Baseline | 0 (0–2) | 0 (0–3) | 0.24 |
End of treatment | 0 (0–3) | 0 (0–3) | 0.63 |
Corpus atrophy | |||
Baseline | 0 (0–1) | 0 (0–1) | 0.54 |
End of treatment | 0 (0–1) | 0 (0–1) | 0.85 |
Antral intestinal metaplasia | |||
Baseline | 0 (0–2) | 0 (0–3) | 0.88 |
End of treatment | 0 (0–3) | 0 (0–3) | 0.91 |
Corpus intestinal metaplasia | |||
Baseline | 0 (0–2) | 0 (0–1) | 0.18 |
End of treatment | 0 (0–1) | 0 (0–1) | 0.45 |